Abstract
enhance clinical efficacy and to avoid toxicity, combination therapy is often used for CRAB 57 infections (4).
58
Eravacycline is a novel fluorocycline that belongs to the tetracycline class of 59 antimicrobials may be a treatment option for CRAB (5). In vitro studies were shown that 60 eravacycline minimum inhibitory concentrations (MICs) were found to be 2-8 fold lower 61 than tigecycline MICs against CRAB (6-8). The drug is also active against colistin resistant 62 strains (9) . Despite in vitro activity, treatment success of eravacycline in CRAB infections are 63 unknown due to lack of clinical trials (10, 11). Management of healthcare-associated 64 infections (HCAI) caused by CRAB should be required combination therapy. There is no in 65 vitro study related to the synergism of eravacycline with other antibiotics in the literature.
66
The aim of this in vitro study is to evaluate the synergistic activity of eravacycline in 67 combination with colistin on CRAB isolates.
68

Results
69
Ten carbapenem-resistant A. baumannii strains were used in this study. MedChemTronica (Sweden) as laboratory-grade powders. All drugs were dissolved with 154 dHO 2 , 6,4 mg/ml stock solutions were prepared for eravacycline and colistin. All stock
155
solutions were stored at -20 °C throughout the study. for MIC determination of the eravacycline/colistin combination.
161
Using 96-well U-bottom microplates, graded concentrations of antibiotics were mixed.
162
Each antimicrobial agent was prepared to a fixed volume of 50 µL (up to a total of 100 µL 
